Reflections from Chicago

While many observers are intently focused on the plenary and oral tumour type sessions at ASCO, in the next couple of posts we will be offering some reflections on some of the hidden gems in the poster halls.

These presentations can afford glimpses into what to expect in future clinical trial readouts in the not too distant future.

Of late many companies have been struggling to raise funding in a tough economic climate, especially if they are powered by a novel target or approach, while others are well funded and settled.

In this example, we discuss a well funded biotech with a novel approach to targeting difficult to treat advanced cancers.  What’s not to like?

To continue reading our latest insights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by